Clinical Trial

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-15.
Status change: Not Yet Recruiting → Recruiting 2024-11-22
Trial Details
NCT Number NCT06222879
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Breast Cancer
Enrollment 350 participants
Start Date 2024-02-20
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-25